Table 5.
Alteration in gene expression by drug treatment
| Effect/stimuli | HepG2 | Hep3B | References |
|---|---|---|---|
| Upregulation of AFP by HBX | Yes | No | Arima et al. (2002) |
| Upregulation of p21 by AG490 | No | Yes | Kusaba et al. (2007) |
| Upregulation of NOX4 by TGF-β | No | Yes | Carmona-Cuenca et al. (2008) |
| Upregulation of FAS by bleomycin | Yes | No | Muller et al. (1997) |
| Upregulation of Bax by AG490 | No | Yes | Kusaba et al. (2007) |
| Upregulation of MMP-3 by PGI/AMF | Yes | No | Yu et al. (2004) |
| Activation of caspase-3 by NK cells | No | Yes | Kim et al. (2004) |
| Stimulation of APP synthesis by OM | Yes | No | Richards et al. (1992) |
| Stimulation of EPO by IL-6 | No | Yes | Jelkmann et al. (1994), Wenger et al. (1998) |
| Induction of LDLR by PMA | 50-fold | 10-fold | Wilson et al. (1997) |
| Lysozyme production by IL-6 | Decrease | Increase | Kobsel and Ramadori (1994) |
| Induction of CYP24A1 by 1,25(OH)2D3 | 5300-fold | 0 | Horvath et al. (2012) |
PGI/AMF: phosphoglucose isomerase/autocrine motility factor; APP: acute phase proteins; OM: oncostatin M; EPO: erythropoietin; LDLR: low density lipoprotein receptor; PMA: phorbo1-12-myristate-13-acetate; 1,25(OH)2D3: 1,25-dihydroxyvitamin D3